AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study

被引：0

作者：

Cortes, Jorge ^{[1
]}

Foran, James ^{[8
]}

Ghirdaladze, Darejan ^{[7
]}

DeVetten, Marcel P. ^{[6
]}

Zodelava, Mamia ^{[5
]}

Holman, Peter ^{[4
]}

Levis, Mark J. ^{[3
]}

Kantarjian, Hagop M. ^{[1
]}

Borthakur, Gautam ^{[1
]}

James, Joyce ^{[2
]}

Zarringkar, Patrick P. ^{[2
]}

Gunawardane, Ruwanthi N. ^{[2
]}

Armstrong, Robert C. ^{[2
]}

Padre, Norman M. ^{[2
]}

Wierenga, Wendell ^{[2
]}

Corringham, Robert ^{[2
]}

Trikha, Mohit ^{[2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Ambit Biosci, San Diego, CA USA

[3] Johns Hopkins Univ, Baltimore, MD USA

[4] Univ Calif San Diego, La Jolla, CA 92093 USA

[5] Hema Clin, Tbilisi, Georgia

[6] Univ Nebraska, Med Ctr, Omaha, NE USA

[7] Medulla Clin, Tbilisi, Georgia

[8] Univ Alabama Birmingham, Birmingham, AL USA

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：264 / 264

页数：1

共 50 条

[1] AC220, A POTENT, SELECTIVE, SECOND GENERATION FLT3 RECEPTOR TYROSINE KINASE (RTK) INHIBITOR, IN A FIRST-IN-HUMAN PHASE 1 AML STUDY
Trikha, M.
Cortes, J.
Foran, J.
Ghirdaladze, D.
DeVetten, M.
Zodelava, M.
Holman, P.
Levis, M.
Kantarjian, H.
Borthakur, G.
James, J.
Armstrong, R.
Zarrinkar, P.
Padre, N.
Wierenga, W.
Corringham, R.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 460 - 461
[2] AC220, A POTENT, SELECTIVE, SECOND GENERATION FLT3 RECEPTOR TYROSINE KINASE (RTK) INHIBITOR, IN A FIRST-IN-HUMAN PHASE 1 AML STUDY
Trikha, M.
Cortes, J.
Foran, J.
Ghirdaladze, D.
Devetten, M.
Zodelava, M.
Holman, P.
Levis, M.
Kantarjian, H.
Borthakur, G.
James, J.
Armstrong, R.
Zarrinkar, P.
Padre, N.
Wierenga, W.
Corringham, R.
ANNALS OF ONCOLOGY, 2010, 21 : 22 - 22
[3] Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor
Cortes, Jorge E.
Ghirdaladze, Darejan
Foran, James M.
DeVetten, Marcel P.
Zodelava, Mamia
Levis, Mark J.
Padre, Norman M.
Joyce, James
Zarrinkar, Patrick P.
Corringham, Robert
BLOOD, 2008, 112 (11) : 284 - 285
[4] AC220 Is a Uniquely Potent and Selective Second-Generation FLT3 Inhibitor
Zarrinkar, Patrick P.
Armstrong, Robert C.
Gunawardane, Ruwanthi N.
James, Joyce
Karaman, Mazen W.
Bhagwat, Shripad S.
BLOOD, 2008, 112 (11) : 318 - 318
[5] INHIBITION OF FLT3 SIGNALING BOTH IN VITRO AND IN VIVO BY AC220, A SECOND GENERATION POTENT AND SELECTIVE FLT3 INHIBITOR
Armstrong, R.
Gunawardane, R.
Rooks, A.
Dao, A.
Ricono, J.
Brigham, D.
Zarrinkar, P.
Belli, B.
Wierenga, W.
ANNALS OF ONCOLOGY, 2010, 21 : 34 - 34
[6] AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Zarrinkar, Patrick P.
Gunawardane, Ruwanthi N.
Cramer, Merryl D.
Gardner, Michael F.
Brigham, Daniel
Belli, Barbara
Karaman, Mazen W.
Pratz, Keith W.
Pallares, Gabriel
Chao, Qi
Sprankle, Kelly G.
Patel, Hitesh K.
Levis, Mark
Armstrong, Robert C.
James, Joyce
Bhagwat, Shripad S.
BLOOD, 2009, 114 (14) : 2984 - 2992
[7] Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3
James, Joyce
Pratz, Keith
Stine, Adam
Apuy, Julius L.
Insko, Darren E.
Armstrong, Robert C.
Zarrinkar, Patrick P.
Small, Donald
Wierenga, Wendell
Levis, Mark J.
BLOOD, 2008, 112 (11) : 912 - 912
[8] Human pharmacokinetics of AC220, a potent and selective class III receptor tyrosine kinase inhibitor
Cortes, Jorge
Foran, James M.
Devetten, Marcel P.
Giles, Francis J.
James, Joyce
Zarrinkar, Patrick P.
Silverman, Michael H.
Kelly, Kerry A.
Padre, Norman M.
Bhagwat, Shripad
Wierenga, Wendell
BLOOD, 2007, 110 (11) : 477A - 477A
[9] Characterization of the biochemical and cellular activity of the second-generation FLT3 inhibitor AC220
Zarrinkar, Patrick
Armstrong, Robert
Gunawardane, Ruwanthi
James, Joyce
Karaman, Mazen
Bhagwat, Shripad
CANCER RESEARCH, 2009, 69
[10] AC220, a uniquely potent and selective FLT3 inhibitor, provides sustained protection in a FLT3 ITD driven model of acute myeloid leukemia
Belli, Barbara
Brigham, Daniel
Breider, Michael
Bhagwat, Shripad
Armstrong, Robert
CANCER RESEARCH, 2009, 69

← 1 2 3 4 5 →